Ludo Reynders joins Premier Research Group
This article was originally published in Clinica
Executive Summary
Contract research organisation Premier Research Group has appointed Ludo Reynders CEO. Dr Reynders was previously CEO of AAIPharma, which he transformed from a pharma company specialising in pain into a drug development services firm. Before this, he worked for Quintiles Translational Corporation for 16 years in several positions including managing director of pharmabio development and CEO of Quintiles Development Services. He was also employed by Bristol Myers for seven years. Philadelphia, Pennsylvania-based Premier Research carries out trials in the analgesia, oncology, neuroscience and cardiovascular fields, and also has experience in medical device and paediatric research.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.